Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc.verified

MRSN

Price:

$2.38

Market Cap:

$291.22M

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name t...[Read more]

Industry

Biotechnology

IPO Date

2017-06-28

Stock Exchange

NASDAQ

Ticker

MRSN

The PE Ratio as of May 2024 (TTM) for Mersana Therapeutics, Inc. (MRSN) is -2.12

According to Mersana Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.12. This represents a change of -35.75% compared to the average of -3.30 of the last 4 quarters.

Mersana Therapeutics, Inc. (MRSN) Historical PE Ratio (quarterly & annually)

How has MRSN PE Ratio performed in the past?

The mean historical PE Ratio of Mersana Therapeutics, Inc. over the last ten years is -8.20. The current -2.12 PE Ratio has changed 2.49% with respect to the historical average. Over the past ten years (40 quarters), MRSN's PE Ratio was at its highest in in the December 2016 quarter at 48.63. The PE Ratio was at its lowest in in the June 2020 quarter at -17.96.

Quarterly (TTM)
Annual

Average

-8.20

Median

-5.10

Minimum

-18.51

Maximum

-1.46

Mersana Therapeutics, Inc. (MRSN) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Mersana Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 525.20%

Maximum Annual PE Ratio = -1.46

Minimum Annual Increase = -85.98%

Minimum Annual PE Ratio = -18.51

Quarterly (TTM)
Annual
YearPE RatioChange
2023-1.57-40.66%
2022-2.641.92%
2021-2.59-85.98%
2020-18.51102.42%
2019-9.14525.20%
2018-1.46-71.34%
2017-5.10-71.45%
2016-17.8819.91%

Mersana Therapeutics, Inc. (MRSN) Average PE Ratio

How has MRSN PE Ratio performed in the past?

The current PE Ratio of Mersana Therapeutics, Inc. (MRSN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-2.27

5-year avg

-6.89

10-year avg

-8.20

Mersana Therapeutics, Inc. (MRSN) PE Ratio vs. Peers

How is MRSN’s PE Ratio compared to its peers?

Mersana Therapeutics, Inc.’s PE Ratio is greater than Terns Pharmaceuticals, Inc. (-4.90), less than Amylyx Pharmaceuticals, Inc. (-1.65), greater than Acumen Pharmaceuticals, Inc. (-3.64), greater than Inozyme Pharma, Inc. (-3.66), less than X4 Pharmaceuticals, Inc. (-1.40), greater than Day One Biopharmaceuticals, Inc. (-5.71), less than HOOKIPA Pharma Inc. (-2.11), greater than Theseus Pharmaceuticals, Inc. (-3.19), greater than Cullinan Oncology, Inc. (-7.84), greater than Relay Therapeutics, Inc. (-2.71), greater than Arcus Biosciences, Inc. (-6.02), greater than Kura Oncology, Inc. (-10.57), less than Protagonist Therapeutics, Inc. (11.42), greater than Merus N.V. (-23.28), less than Replimune Group, Inc. (-1.49), greater than Cerevel Therapeutics Holdings, Inc. (-16.30), greater than Pliant Therapeutics, Inc. (-4.49), greater than Syndax Pharmaceuticals, Inc. (-7.18), greater than Revolution Medicines, Inc. (-12.91), greater than Viridian Therapeutics, Inc. (-3.39),

Build a custom stock screener for Mersana Therapeutics, Inc. (MRSN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mersana Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Mersana Therapeutics, Inc. (MRSN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Mersana Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Mersana Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Mersana Therapeutics, Inc. (MRSN)?

What is the highest PE Ratio for Mersana Therapeutics, Inc. (MRSN)?

What is the 3-year average PE Ratio for Mersana Therapeutics, Inc. (MRSN)?

What is the 5-year average PE Ratio for Mersana Therapeutics, Inc. (MRSN)?

How does the current PE Ratio for Mersana Therapeutics, Inc. (MRSN) compare to its historical average?